Buprenorphine-Fentanyl Interaction Study

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 22, 2018

Primary Completion Date

January 4, 2019

Study Completion Date

January 4, 2019

Conditions
HealthyOpioid Use
Interventions
DRUG

Buprenorphine Injectable Solution - Part A

"Buprenorphine intravenous (IV) injection given as a primed-continuous infusion.~Low Dose: initial bolus (0.05 mg/70 kg) administered over 15 minutes and infusion continued (0.02 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 0.2 ng/ml.~High Dose: initial bolus (0.125 mg/70 kg) administered over 15 minutes and infusion continued (0.05 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 0.5 ng/ml.~Administration of buprenorphine was flexible and infusion rates were selected to target approximately 25 to 50% respiratory depression."

DRUG

Placebo - Parts A + B

0.9% normal saline for IV administration was used as placebo matching the buprenorphine formulation and administration.

DRUG

Fentanyl - Part A

Participant received up to four fentanyl doses: 0.075, 0.15, 0.25, and 0.35 mg/70 kg in Periods 1 and 2. Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo. Administration of fentanyl was flexible and bolus doses were selected to elicit moderate to more severe respiratory depression with apnoea ≥20 seconds.

DRUG

Ondansetron - Parts A + B

A non-investigational intervention administered as an infusion prior to investigation intervention. 4 mg of ondansetron was administered to manage the expected gastrointestinal side effect (nausea, vomiting) to buprenorphine.

DRUG

Buprenorphine Injectable Solution - Part B

"Buprenorphine intravenous (IV) injection given as a primed-continuous infusion.~Low Dose: initial bolus (0.25 mg/70 kg) administered over 15 minutes and infusion continued (0.1 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 1 ng/ml.~Mid Dose: initial bolus (0.5 mg/70 kg) administered over 15 minutes and infusion continued (0.2 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 2 ng/ml.~High Dose: initial bolus (1.25 mg/70 kg) administered over 15 minutes and infusion continued (0.5 mg/70 kg/hour infusion rate) to complete 360 minutes of administration targeting 5 ng/ml."

DRUG

Fentanyl - Part B

"Participant received up to four fentanyl doses: 0.25, 0.35, 0.5, and 0.7 mg/70 kg in Periods 1 and 2.~Fentanyl boluses were administered over 90 seconds by dose escalation +2hr, +3hr, +4hr and +5hr after starting administration of buprenorphine/ placebo."

DRUG

Oxycodone - Part B

All opioid-tolerant participants in Part B were transitioned to oral oxycodone at least 48 hours before Period 1 to ensure washout of the participants' regular opioids and a stable dose of oxycodone with an adequate bridging schedule reached. Oxycodone is a non-investigational intervention.

Trial Locations (1)

Unknown

Center for Human Drug Research, Leiden

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Indivior Inc.

INDUSTRY

NCT03747341 - Buprenorphine-Fentanyl Interaction Study | Biotech Hunter | Biotech Hunter